Main Article Content
Carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 are tumor markers for colorectal cancer (CRC), both having prognostic value. According to the Colorectal Working Group of the American Joint Committee on Cancer, increases in CEA and CA 19-9 levels of >5 µg/l and > 37 U/ml, respectively, are considered abnormal. Increased serum CEA may be encountered in postoperative CRC patients from recurrences or metastases. There are no research data in Indonesia on the characteristics of CEA and CA 19-9 levels according to preoperative CRC cellular differentiation. The objective of this study was to determine differences in serum CEA and CA 19-9 levels according to CRC cellular differentiation.
This was a cross-sectional study conducted on 40 CRC subjects from July 2012 until May 2013. Determination of serum CEA and CA 19-9 levels and histopathological (cellular) differentiation grades in CRC biopsies was done in all subjects.
The study involved forty CRC patients, consisting of 22 males and 18 females, with mean age of 51.93 ± 11.63 years, CEA levels of 51.93 ± 84.07 ng/ml and CA 19-9 levels of 33.81 ± 62.39 U/ml. Carcino-embryonic antigen levels tended to decrease with decreasing CRC histopathological grade, while CA 19-9 levels increased in well-differentiated CRC. However, both relationships were statistically not significant (with p=0.314 and p=0.787, respectively).
Carcinoembryonic antigen (CEA) levels tend to decrease with decreasing histopathological grade of CRC, and CA 19-9 levels tend to increase in well-differentiated CRC.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
Jemal A, Bray F, Center M. Global cancer statistic. CA Cancer J Clin 2011;61:69-90.
Abdullah M. Tumor kolorektal: distribusi kanker kolorektal menurut lokasi di kolon. In: Sudoyo AW, Setiyohadi B, Alwi I, Marcellus SK, Setiati S, editors. Buku Ajar Ilmu Penyakit Dalam. 5th ed. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran Indonesia; 2009. p. 567-75.
Abdullah M, Sudoyo AW, Utomo AR, Fauzy A, Rani AA. Molecular profile of colorectal cancer in Indonesia: is there another pathway Gastroenterol Hepatol Bed Bench 2012;5:71-8.
Effendi R, Efendi D, Dairy LB, Sembiring J, Sihombing M, Marpaung B, et al. Profile of colorectal cancer patients in endoscopic unit at Pirngadi Hospital Medan. Indonesian J Gastroenterol Hepatol Dig Endosc 2008;9:758.
Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, et al. Is it reasonable to add preoperative serum level of CEA and CA 19-9 to staging for colorectal cancer? J Surg Res 2005; 124:169-74.
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendation for use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
Weissenberger C, Von Plehn G, Otto F, Barke A, Momm F, Geissler M. Adjuvant radio chemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9. Anticancer Res 2005;25:1787-94.
Yang XQ, Chen C, Wang FB, Peng CW, Li Y. Preoperative serum carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125 as prognostic factors for recurrencefree survival in colorectal cancer. Asian Pacific J Cancer Prev 2011;12:1251-6.
Casciato DA. Manual of clinical oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2012.
Stewart SL, Wike JM, Kato I, Lewis DR, Michaud F. A population based study of colorectal cancer histology in the United Stated 1998-2001. Cancer 2006;107:1128-41.
Sudoyo AW, Hernowo B, Krisnuhoni E, Reksodiputro AH, Hardjodisastro D, Sinuraya ES. Colorectal cancer among young native Indonesians: a clinicopathological and molecular assessment on microsatellite instability. Med J Indonesia 2010;19:245-51.
Capple MS. The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Med Clin North Am 2005; 89:1-42.
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001;47:624-30.
Morita S, Nomura T, Fukushima Y, Morimoto T. Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer. Dis Colon Rectum 2004;47:22732. doi: 10.1007/s1035000 3-0041-6.
Compton C, Fenoglio-Preiser CM, Petigrew N, Fielding CP. American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer 2000;88:1739-57.
Cerna M, Holubec L, Pesta M, Kormunda S, Topolcan O, Cerny R. Quantitative estimation of CEA and CK20 expression in tumour tissue of colorectal cancer and its liver metastases with reverse transcription and real-time PCR. Anticancer Res 2006;26:803-8.
Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility ofbiochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-27.